ALNY vs. BIO: Alnylam Pharmaceuticals vs. Bio-Rad Laboratories Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and Bio-Rad Laboratories (BIO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while BIO is classified in Life Sciences Tools & Services.
| Profile Item | ALNY | BIO |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | Bio-Rad Laboratories Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 20.89 billion USD | 10.26 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | June 1, 2004 | February 27, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | BIO |
|---|---|---|
| Total Return (1Y) | -64.57% | 28.31% |
| Total Return (3Y, Annualized) | -1.58% | 8.52% |
| Total Return (5Y, Annualized) | -3.13% | -11.74% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ALNY | BIO |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 36.50% |
| Beta (5Y) | 0.45 | 1.03 |
| Max Drawdown (5Y) | -68.25% | -72.24% |
| Avg. Volume (3M) | 1.90M | 250.78K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | BIO |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | 0.66 |
| Sortino Ratio (1Y) | -1.45 | 0.98 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Bio-Rad Laboratories (BIO) at 14.27% also sits in the top quartile.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 52.85% and Bio-Rad Laboratories (BIO) at 39.45% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Alnylam Pharmaceuticals (ALNY) at 23.72% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.82%
- Max
- 83.12%
- Q3
- 14.77%
- BIO
- 11.82%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | BIO |
|---|---|---|
| ROE (TTM) | 138.07% | 14.27% |
| ROA (TTM) | 9.51% | 1.50% |
| Net Margin (TTM) | 52.85% | 39.45% |
| Operating Margin (TTM) | 23.72% | 11.82% |
| Gross Margin (TTM) | 77.28% | 52.19% |
Growth
Revenue Growth
Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Bio-Rad Laboratories (BIO) at 0.65% is closer to the peer norm — faster top-line expansion for ALNY.
EPS Growth
Neither Alnylam Pharmaceuticals (ALNY) nor Bio-Rad Laboratories (BIO) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ALNY | BIO |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | 0.65% |
| Revenue Growth (3Y CAGR) | 52.98% | -2.68% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Alnylam Pharmaceuticals (ALNY) at 2.48 and Bio-Rad Laboratories (BIO) at 3.18 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO
- 3.18
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Bio-Rad Laboratories (BIO) at 0.18 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ALNY | BIO |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | 3.18 |
| Debt / Equity (MRQ) | 0.83 | 0.18 |
| Net Debt / EBITDA | -0.57 | -0.73 |
Dividends
Dividend Yield (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor Bio-Rad Laboratories (BIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor Bio-Rad Laboratories (BIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | BIO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 7.88 and Bio-Rad Laboratories (BIO) at 10.14 sit in the cheaper earnings-multiple quartile for P/E ratio, with the market paying less for a dollar of trailing earnings than it pays for typical peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.14
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO
- 10.14
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Bio-Rad Laboratories (BIO) at 3.96 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.96
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO
- 3.96
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while Alnylam Pharmaceuticals (ALNY) at 5.79 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO
- 1.35
- Min
- -5.59
Valuation Metrics
| Metric | ALNY | BIO |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | 10.14 |
| P/S Ratio (TTM) | 4.17 | 3.96 |
| P/B Ratio (MRQ) | 5.79 | 1.35 |
| Free Cash Flow Yield (TTM) | 1.57% | 2.65% |